Tufts CSDD Releases Results of New Impact Report

Published on: March 8, 2017

A recently completed study reported that the 505(b)(2) approval pathway for new drug applications in the US has not led to shorter approval times.

A recently completed study conducted by Tufts CSDD reported that the 505(b)(2) approval pathway for new drug applications in the US, aimed at avoiding the duplication of studies performed on a previously approved drugs, has not led to shorter approval times.

Read the full release here